해당 제품을 고객님의 쇼핑 카트 또는 즐겨찾기에 추가하는 경우를 제외하고 종료는 고객님의 맞춤정보를 저장하지 않습니다.
해당 멀티플렉스® MAP 도구를 종료하려면 확인을 클릭하거나 고객님의 선택사항으로 복귀하려면 취소를 클릭하십시오.
밀리플렉스® MAP 키트의 디자인 및 가격 설정.
머크 밀리포아의 광범위한 포트폴리오는 해당 패널 안에서, 고객님의 필요에 가장 잘 부합하는 분석물을 선택하도록 허용하는 멀티플렉스로 구성되어 있습니다. 별도의 탭에서 사전 혼합된 시토카인(cytokine) 형식 또는 단일 플렉스 키트를 선택할 수 있습니다.
전체 경로 또는 과정을 탐색하도록 허용하는 수리된 키트를 선택하십시오. 또는 단일 플렉스 MAP메이트™를 선택하여 제공된 지침에 따라 고객님 고유의 키트를 디자인하십시오.
다음 MAP메이트™는 통합될 수 없습니다:
-다른 분석 완충용액이 필요한 MAP메이트™.
-인산 특이성 및 총 MAP메이트™ 조합, 예: 총 GSK3β 및 GSK3β(Ser 9).
-PanTyr 및 자리 특이성 MAP메이트™, 예: Phospho-EGF 수용체 및 phospho-STAT1(Tyr701).
-단일 표적(Akt, STAT3)를 위한 1개 이상의 1 phospho-MAP메이트™.
- GAPDH 및 β-Tubulin은 panTyr를 포함하는 키트 또는 MAP메이트™와 통합될 수 없습니다.
.
카탈로그 번호 | 주문 설명 | 포장 단위 | 목록 |
밀리플렉스® MAP 키트를 디자인하려면 종, 패널 유형 또는 관심있는 키트를 선택하십시오.
종 |
패널 유형 |
선택하신 키트 |
시료 유형: |
수정 |
종 선택 | . |
패널 유형 선택 | . |
키트 선택 | . |
시료 유형 선택 | 일부 패널의 경우, 시료 유형이 어느 분석물이 함께 통합될지 결정합니다. |
고객님 고유의 키트를 디자인하거나 머크 밀리포아의 사전 혼함된 단일 플렉스 패널에서 선택하십시오.
Catalogue Number | Ordering Description | Qty/Pack | List |
종 | |
패널 유형 | |
선택하신 키트 | |
수량 | 카탈로그 번호 | 주문 설명 | 포장 단위 | 기재 가격 |
96-Well Plate |
수량 | 카탈로그 번호 | 주문 설명 | 포장 단위 | 기재 가격 |
수량 | 카탈로그 번호 | 주문 설명 | 포장 단위 | 기재 가격 |
48-602MAG | Buffer Detection Kit for Magnetic Beads | 1 Kit |
이제 다른 키트를 사용자 지정하거나, 사전 혼합된 키트를 선택하거나, 결재하거나 또는 주문 도구를 종료할 수 있습니다.
View upcoming and on-demand webinars to learn advanced research techniques, valuable tips and advice from leaders in their fields of scientific research.
|
Abstract: Join us to learn about challenges faced with traditional expression systems and how a CHO cell line with the glutamine synthetase knock-out via ZFN provides benefits for fast, efficient cell line development with stable and high titer expression. CHO cells with their unique characteristics, represent the major expression system within the biopharmaceutical industry. However, one of the major challenges in cell line development is to identify those rare, high-producing clones in a huge population of non-expressing or low-expressing cell lines. This leads to laborious and time consuming cell line development processes. This webinar will educate the audience about challenges faced with traditional expression systems and how the CHO cell line with the glutamine synthetase knock-out via Zinc Finger Nucleases provides benefits for fast and efficient cell line development as well as stable and high titer expression. We will explore additional cell line engineering targets that can be modified to engineer a cell line that mitigates risks and removes bottlenecks throughout the biopharmaceutical process. In this webinar, you will learn:
|
|
Abstract: Every biopharma executive must make important decisions early in clinical development that will impact their molecule’s journey – and ultimately the success of their commercial strategy. The key to this success is to make the right decisions at the right time. In this webinar, our experts share some key considerations to help biopharmaceutical companies successfully advance a molecule from the laboratory to the clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety. To achieve this goal, companies must navigate the complexities associated with business planning, cell line development, process development, technology, and regulatory and risk assessment. In this webinar, you will learn:
|
|
Abstract: This webinar will provide a comprehensive, holistic assessment of the effects of Clarisolve® mPAA flocculation polymer pre-treatment upon clarification and subsequent downstream chromatography steps. Flocculation is a simple method to pre-clarify high density Chinese hamster ovary (CHO) cell culture feed streams, allowing for an efficient clarification process that would otherwise not be feasible using traditional depth filters. Clarisolve® mPAA polymer is a stimulus-responsive flocculation polymer that may provide a reduced dosing dependency and lower residual polymer levels when compared to other flocculants. Cell culture pre-treatment with Clarisolve® mPAA polymer followed by clarification using Clarisolve® 60HX depth filters, enables a significant increase of harvest throughputs and allows for a single clarification stage for these high-density feed streams. Furthermore, by eliminating the need for centrifugation, pre-treatment with Clarisolve® mPAA polymer allows for the implementation of a single-use clarification train.This webinar will review the efficacy of pretreatment with a range of Clarisolve® mPAA polymer concentrations upon the clarification and purification of a CHO cell culture feed stream. These results were compared to material prepared using conventional Millistak+® HC depth filtration media to deliver a comprehensive, holistic assessment of the effects of Clarisolve® mPAA polymer pre-treatment upon the clarification and subsequent downstream chromatography steps. In this webinar, you will learn more about:
|
|
Abstract: This webinar highlights regulations for plastic devices in pharmaceutical manufacturing, a risk-based approach to qualifying components, and the importance of regulatory documentation. The growing complexity of therapeutics and globalization are some of the factors leading to innovative manufacturing solutions. Thanks to their flexibility and ease of use, polymeric materials are being used more frequently in the manufacturing of pharmaceuticals and biopharmaceuticals. Consequently, the development and qualification of plastic components requires a purposeful implementation of a multifaceted regulatory guidance. However, the lack of regulations specific to plastics used in pharmaceutical manufacturing systems has led to considerable uncertainty. In this webinar, you will learn:
|
Session 1: 3:00 AM EST, 12 AM PST, 9 AM CET View your Time Zone start time
Register Now Session 2: 11:00 AM EST, 8 AM PST, 5 PM CET View your Time Zone start time
Register Now |
Abstract: This webinar will discuss appropriate quality attributes for different raw material uses, present strategies to support identification, selection and risk assessment of raw materials, and highlight the importance of regulatory documentation. Recent and continuing regulatory improvements require drug manufacturers to assess and mitigate risk throughout their entire processes. This includes raw materials used at every stage of manufacturing and clinical phases. Current regulatory guidelines and industry standards clearly define quality requirements for raw materials that are incorporated into, or used close to, final drug product, for example active ingredients and excipients. However, no such clear standards are defined for chemicals used earlier in the process, such as in upstream bioprocessing, early chemical synthesis stages, or clean-in-place. The absence of such standards presents a challenge to efficiently and effectively source raw materials with appropriate supply chain transparency and control, accompanied by the necessary supporting documentation. In this webinar, you will learn:
|